In the present study, we explored the Genomics of Drug Sensitivity in Cancer (GDSC) database to estimate the significance of TP53 mutation in bladder cancer drug selection, and analyzed RNA sequencing (RNA-Seq) dataset of MIBC to find out the role of TP53 mutation in disease progression, providing novel individualized treatment options. This evidence concerns the gene TP53 and cancer.